Robert Alonso
18Patents
3h-index
10Co-inventors
53Inventor score
Filing activity: Mar 7, 2006 → Oct 17, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9974755B2 | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases | Human Necessities | 7 | Active |
| US7838564B2 | Stabilized compositions of volatile alkylating agents and methods of using thereof | Emerging Cross-Sectional Technologies | 4 | Active |
| US9763896B2 | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases | Human Necessities | 3 | Active |
| US8664278B2 | Stabilized compositions of volatile alkylating agents and methods of using thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US7872050B2 | Stabilized compositions of volatile alkylating agents and methods of using thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US10220006B2 | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of Neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases | Human Necessities | 2 | Active |
| US8501817B2 | Stabilized compositions of alkylating agents and methods of using same | Human Necessities | 1 | Active |
| US8501818B2 | Stabilized compositions of alkylating agents and methods of using same | Human Necessities | 1 | Active |
| US8450375B2 | Stabilized compositions of volatile alkylating agents and methods of using thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US8501819B2 | Stabilized compositions of volatile alkylating agents and methods of using thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US10864173B2 | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases | Human Necessities | 1 | Active |
| US11504384B1 | Compositions and methods for treatment of skin infections | Human Necessities | 1 | Active |
| US11717497B2 | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases | Human Necessities | 0 | Active |
| US9382191B2 | Stabilized compositions of volatile alkylating agents and methods of using thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US10744174B1 | Composition(s) and method(s) for topically treating pain | Human Necessities | 0 | Active |
| US10548900B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | Chemistry; Metallurgy | 0 | Active |
| US11406642B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | Chemistry; Metallurgy | 0 | Active |
| US11833161B2 | Compositions and methods for treatment of skin infections | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.